Is diffusion-weighted MRI sufficient for follow-up of neuroendocrine tumour liver metastases?
Authors:
- 1 September 2016
- journal article
- Published by Elsevier in Clinical Radiology
- Vol. 71 (9) , 863-868
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Staging of gastroenteropancreatic neuroendocrine tumors: how we do it based on an evidence-based approachClinical Imaging, 2013
- ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown PrimaryNeuroendocrinology, 2012
- Hepatic Metastases From Neuroendocrine Tumors With a “Thin Slice” Pathological ExaminationAnnals of Surgery, 2010
- Diffusion-weighted MR Imaging of the LiverRadiology, 2010
- Detection of Neuroendocrine Liver Metastases with MnDPDP-Enhanced MRINeuroendocrinology, 2008
- Are Metastases Really Hypovascular in the Arterial Phase?Journal of Ultrasound in Medicine, 2007
- Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localizationEndocrine-Related Cancer, 2005
- Endocrine pancreatic tumors: factors correlated with survivalAnnals of Oncology, 2005
- MR Imaging of Hepatic Metastases Caused by Neuroendocrine Tumors: Comparing Four TechniquesAmerican Journal of Roentgenology, 2003
- Prognostic factors in patients with endocrine tumours of the duodenopancreatic areaGut, 1998